These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24001230)

  • 1. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
    Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
    Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of non-macrocyclic small molecule inhibitors against the NS3/4A serine protease of hepatitis C virus through in silico screening.
    Chaudhuri R; Lee H; Truong L; Torres J; Patel K; Johnson ME
    J Chem Inf Model; 2012 Aug; 52(8):2245-56. PubMed ID: 22697413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational drug discovery: Ellagic acid as a potent dual-target inhibitor against hepatitis C virus genotype 3 (HCV G3) NS3 enzymes.
    Lim SK; Othman R; Yusof R; Heh CH
    Chem Biol Drug Des; 2021 Jan; 97(1):28-40. PubMed ID: 32657543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
    Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
    Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
    J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of small molecule inhibitors against the NS3/4A serine protease of Hepatitis C virus genotype 3 via highthroughput virtual screening and in vitro evaluations.
    Sakhor W; Teoh TC; Yusof R; Lim SK; Razif MFM
    Trop Biomed; 2020 Sep; 37(3):609-625. PubMed ID: 33612776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
    Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
    J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing and molecular docking of cyclic peptides against HCV NS3 protease.
    Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA
    Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral phytochemicals identification from Azadirachta indica leaves against HCV NS3 protease: an in silico approach.
    Ashfaq UA; Jalil A; Ul Qamar MT
    Nat Prod Res; 2016 Aug; 30(16):1866-9. PubMed ID: 26274064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.
    Lee H; Zhu T; Patel K; Zhang YY; Truong L; Hevener KE; Gatuz JL; Subramanya G; Jeong HY; Uprichard SL; Johnson ME
    PLoS One; 2013; 8(10):e75144. PubMed ID: 24130685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.
    Guan Y; Sun H; Li Y; Pan P; Li D; Hou T
    Antiviral Res; 2014 Mar; 103():60-70. PubMed ID: 24462696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
    Thomson JA; Perni RB
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus.
    Samantaray M; Pattabiraman R; Murthy TPK; Ramaswamy A; Murahari M; Krishna S; Kumar SB
    J Biomol Struct Dyn; 2024 Oct; 42(16):8505-8522. PubMed ID: 37646701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
    Wadood A; Riaz M; Uddin R; Ul-Haq Z
    PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.